Ten percent owner of Oncology Institute (NASDAQ: TOI) adds 30,000 shares in open-market buy

Rhea-AI Filing Summary

Oncology Institute, Inc. insider Jorey Chernett, identified as a ten percent owner, reported an open-market purchase of common stock. Chernett bought 30,000 shares on May 19, 2026 at a price of $4.09 per share. After this transaction, Chernett directly owns 10,529,358 common shares, indicating the purchase modestly increased an already large existing position.

Insider Trade Summary

Net Buyer: 30,000 shares ($122,700)

Net Buy 1 txn

Insider Chernett Jorey

Role null

Bought 30,000 shs ($123K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	30,000	$4.09	$123K

Holdings After Transaction: Common Stock — 10,529,358 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 30,000 shares Purchase price: $4.09 per share Shares owned after transaction: 10,529,358 shares +2 more

5 metrics

Shares purchased 30,000 shares Open-market purchase of common stock on May 19, 2026

Purchase price $4.09 per share Price paid for TOI common stock on May 19, 2026

Shares owned after transaction 10,529,358 shares Direct ownership following the May 19, 2026 purchase

Net buy shares 30,000 shares Net result of reported Form 4 transactions

Buy transactions count 1 transaction Number of buy entries in the Form 4

Key Terms

open-market purchase, Form 4, non-derivative, ten percent owner

4 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

""transaction_type": "non-derivative""

ten percent owner regulatory

""is_ten_percent_owner": 1"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chernett Jorey

(Last) (First) (Middle)

6222 INDIANWOOD TR.

(Street)

BLOOMFIELD HILLS MICHIGAN 48301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		P		30,000	A	$4.09	10,529,358	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $4.04 to $4.14, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.

	/s/ Jorey Chernett	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did TOI’s Jorey Chernett report on this Form 4?

Jorey Chernett reported buying 30,000 shares of Oncology Institute common stock. The open-market purchase occurred on May 19, 2026 at a price of $4.09 per share, increasing Chernett’s direct ownership position in the company.

At what price did Jorey Chernett buy Oncology Institute (TOI) shares?

Chernett bought the shares at $4.09 each in an open-market transaction. This fixed price applies to all 30,000 common shares reported, giving investors a clear view of the level at which the ten percent owner added exposure.

How many Oncology Institute (TOI) shares does Jorey Chernett own after the reported trade?

Following the reported purchase, Chernett directly owns 10,529,358 shares of Oncology Institute common stock. This total reflects the addition of 30,000 shares acquired on May 19, 2026 through the open-market buy at $4.09 per share.

Was the TOI insider transaction by Jorey Chernett a purchase or a sale?

The transaction was a purchase of common stock in the open market. The Form 4 classifies it with code “P,” indicating an open-market or private purchase, and shows no corresponding sales or derivative transactions on the same date.

How large was Jorey Chernett’s TOI share purchase compared with the reported holdings?

Chernett bought 30,000 shares, bringing total direct ownership to 10,529,358 shares. The filing highlights that this trade adds to an already substantial stake held by a ten percent owner, without reporting any offsetting sales or derivative exercises.